January 16, 2024 02:54 PM EST

A decade after its first FDA approval, Takeda expands label of HyQvia to include rare autoimmune disorder

Zachary Brennan

Senior Editor

The FDA on Monday extended the label for Takeda’s HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) as a maintenance therapy to prevent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A decade after its first FDA approval, Takeda expands label of HyQvia to include rare autoimmune disorder

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?

A decade af­ter its first FDA ap­proval, Take­da ex­pands la­bel of HyQvia to in­clude rare au­toim­mune dis­or­der

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A decade after its first FDA approval, Takeda expands label of HyQvia to include rare autoimmune disorder

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?